Differential Outcomes with Empagliflozin and Dapagliflozin in Heart Failure with Mildly Reduced Ejection Fraction
In this large real-world HFmrEF population, empagliflozin was associated with lower mortality, hospitalization, and HF exacerbation compared with dapagliflozin, with no significant difference in UTI risk. These findings suggest potential heterogeneity in clinical effectiveness among SGLT2 inhibitors in HFmrEF and warrant confirmation in prospective comparative studies.
Authors
- Ayushi Sahu
- Khaled Chatila
- Shareef Mansour
- Thomas Blackwell
- Aaron M. Lee (ORCID: https://orcid.org/0000-0001-6008-5366)
- Krishna K Paul (ORCID: https://orcid.org/0000-0002-9829-1250)
- Dietrich Jehle
- Hani Jneid
- Ibrahim Mortada
- Yazeed Alhanbali
- Erin Vidal
Institutions
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-01-12
- DOI
- https://doi.org/10.64898/2026.01.09.26343819
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00